Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.

LXRX has been the topic of a number of other reports. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Piper Sandler reduced their price target on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals in a research note on Friday. They set a “sell” rating for the company. Finally, Leerink Partners restated a “market perform” rating and issued a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Stock Up 64.1 %

LXRX stock opened at $0.57 on Friday. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.45. The firm has a fifty day moving average price of $0.61 and a two-hundred day moving average price of $1.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. The business had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. Research analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bayesian Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $31,000. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $33,000. Renaissance Technologies LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth $38,000. Arizona State Retirement System lifted its holdings in shares of Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 24,615 shares during the period. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.